Scleroderma

Autologous stem-cell transplantation improves survival in scleroderma patients: The SCOT trial

January 05, 2018

Scleroderma patients treated with myeloablative autologous stem-cell transplantation experienced significantly higher rates of disease-free survival at 52 months post-treatment compared to those treated with cyclophosphamide.